AZN Company Profile and Key Details

NYSE : AZN

AstraZeneca

$195.15

11.29+6.14%

Open: 4:00 PM

67.8

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

AstraZeneca PLC (AZN) stock surged +6.14%, trading at $195.15 on NYSE, up from the previous close of $183.86. The stock opened at $189.52, fluctuating between $189.17 and $196.41 in the recent session.

Stock Snapshot

183.86

Prev. Close

302.65B

Market Cap

189.1651

Day Low

21.07

P/E Ratio

9.26

EPS (TTM)

2.1

Cash Flow per Share

189.52

Open

1.55B

Number of Shares

196.41

Day High

49.82%

Free Float in %

12.54

Book Value

2.27M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 02, 2026	189.52	196.41	189.17	195.15	2.37M
Jul 01, 2026	187.07	187.65	183.49	183.86	2.11M
Jun 30, 2026	190.31	190.46	186.16	189.62	2.6M
Jun 29, 2026	189.25	191.13	188.45	190.95	1.61M
Jun 26, 2026	184.28	189.57	184.28	188.41	3.22M
Jun 25, 2026	184.82	186.58	184.55	185.68	1.83M
Jun 24, 2026	183.40	184.61	182.19	183.02	2.38M
Jun 23, 2026	179.81	181.15	179.28	181.02	1.49M
Jun 22, 2026	175.29	177.43	175.11	176.43	1.49M
Jun 18, 2026	177.67	177.80	173.66	174.93	1.66M
Jun 17, 2026	178.70	180.44	177.65	177.89	1.87M
Jun 16, 2026	178.33	179.12	176.64	178.71	1.89M
Jun 15, 2026	179.16	179.22	176.55	177.27	1.32M
Jun 12, 2026	182.53	182.70	178.59	178.75	2.39M
Jun 11, 2026	181.36	183.67	180.39	182.28	1.67M
Jun 10, 2026	180.94	181.72	177.88	178.96	2.03M
Jun 09, 2026	181.73	183.81	181.16	183.43	1.88M
Jun 08, 2026	184.16	185.31	181.36	181.55	2.04M
Jun 05, 2026	184.02	186.12	184.02	185.95	2.34M
Jun 04, 2026	180.58	183.37	180.24	181.80	2.03M

Contact Details

Cambridge, CB2 0AA

United Kingdom

https://www.astrazeneca.com 442 037 495000

About Company

AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.

Stock Peers

LLY

18.76+1.57%

Eli Lilly and Company$1,210.50 JNJ

9.06001+3.57%

Johnson & Johnson$263.04 ABBV

10.01001+3.99%

AbbVie Inc.$261.07 NVS

5.76+3.74%

Novartis AG$159.90 MRK

4.14999+3.31%

Merck & Co., Inc.$129.52 ZTS

2.35+3.24%

Zoetis Inc.$74.80 BMY

1.69+2.99%

Bristol-Myers Squibb Company$58.13 GSK

2.36+4.60%

GSK plc$53.66 NVO

1.66+3.40%

Novo Nordisk A/S$50.43 PFE

0.44+1.84%

Pfizer Inc.$24.32

Company Overview

AstraZeneca PLC (NYSE:AZN) closed at $195.15 USD, gaining $11.29 (6.14%) from the previous close of $183.86. The stock is currently mid-range between its 52-week high and low $137.22 and $212.71. With a market capitalization of about $302.65 billion, AstraZeneca PLC is classified as a mega-cap and shows lower-than-market volatility (beta ~0.21). Key stats such as the average daily volume over the past year has been around 1.98 million shares, in line with its 52-week average. Headquartered in Cambridge, None, AstraZeneca PLC operates in the Healthcare sector and the Drug Manufacturers - General industry. Led by CEO Pascal Claude Roland Soriot, the company employs approximately 94,300 people and listed since May 12, 1993. AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 3.04%, SMA50 7.55%, SMA200 25.28%). The stock’s 14-day RSI is 59.1 (neutral), while the ATR of 5.31 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -4.1% below its high and over 66.84% above its low. Average 10-day trading volume of 2.29 million shares is slightly above the 3-month average of 1.95 million, indicating heightened recent market interest.

Valuation Metrics

AstraZeneca PLC trades at a P/E ratio of 29.08, slightly below the S&P 500 average, with a price-to-sales ratio of 5.01 and a price-to-book ratio of 6.39 trading at moderately above to book value. The P/FCF stands at 37.51, also above market averages.

Dividend & Fair Value

AstraZeneca PLC last paid a dividend of 3.2 per share, this equals a trailing yield of roughly 3.72%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $367.22. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

AstraZeneca PLC generated EPS of $6.55 over the past year. Five-year average earnings growth is 22.05%. Wall Street analysts project EPS growth of 11.8% annually over the next five years. The latest quarter delivered EPS of $2.58. The next quarter is forecast at $2.49. Next year's EPS is expected at $14.05. AstraZeneca PLC earnings surprise history is a mixed track record. The quarter that ended April 29, 2026, missed forecasts by 2.79%. The prior quarter beat by -2.75%. Over the last six quarters, Apple has recorded several small beats. These include -1.87% in February 06, 2025.

Shareholding & Insider Activity

AstraZeneca PLC has 1.55 billion shares outstanding. The public float is 1.54 billion shares, elevated short interest at 0.09% of float. This equals 1.33 million shares. The short ratio is 0.68 days. Institutional investors hold 16.73% of the float. Insiders own 0.0%. Over the past six months, insider transactions show net selling. They sold 11.89 thousand shares across 1 transactions.

Financial & Profitability Overview

Over the trailing twelve months, AstraZeneca generated $45.81B in revenue, or $14.66 per share. Gross margin was 81.95%, operating margin 17.88%, and net profit margin 13.00%. Returns are healthy, with ROA at 5.89% and ROE at 15.21%.
On valuation metrics, AstraZeneca trades at a P/E of 29.08, P/S of 5.01 and P/B of 6.39. Liquidity is tight, with a current ratio of 0.91 and quick ratio of 0.71. Operationally, the company’s inventory turnover is 1.68 and cash conversion cycle is -440.22 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.72, supported by a cash flow-to-debt ratio of 0.42.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, AstraZeneca posted revenue of $45.81B, down slightly from $44.35B in the prior quarter. Gross profit was $37.54B (margin 81.95%). Operating income was $8.19B (margin 17.9%). Net income was$5.96B (EPS $1.92).
The company ended the quarter with $5.86B in cash and short-term investments, a total debt of $28.62B, and net debt of $22.78B. Total assets were $101.12B, with equity of $39.17B. Financials further reflected stability, with operating cash flow of $10.35B, free cash flow of $6.57B, and capital expenditures of - $3.78B.

Price Forecast & Outlook

Our AI price prediction model suggests that AstraZeneca PLC stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 5.55%, with price expected at $205.99 by July 16, 2026, within a range of $201.94 to $209.90 3-Month Outlook: Projected fall of -80.2%, reaching $38.64 by September 30, 2026, with a range of $24.36 to $41.70. 1-Year Outlook: Projected gain of 12.85%, with price at $220.22 by July 02, 2027, within a range of $208.69 to $231.69.

Key Takeaways

AstraZeneca PLC (NYSE:AZN) shares are flat -2.16% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows AstraZeneca PLC trading at a premium to the broader market with a P/E of 29.08. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $79.75, suggesting -59.13% downside. Our AI forecast model points to short-term strength (5.55% over two weeks), a medium-term fall (-80.2% over three months), and a longer-term gain (12.85% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current AstraZeneca PLC (AZN) stock price?

AstraZeneca PLC (NYSE: AZN) stock price is $195.15 in the last trading session. During the trading session, AZN stock reached the peak price of $196.41 while $189.17 was the lowest point it dropped to. The percentage change in AZN stock occurred in the recent session was 6.14% while the dollar amount for the price change in AZN stock was $11.29.

AZN's industry and sector of operation?

The NYSE listed AZN is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector. AstraZeneca PLC designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of AZN?

No Data

How AZN did perform over past 52-week?

AZN's closing price is 42.22% higher than its 52-week low of $137.22 where as its distance from 52-week high of $212.71 is -8.26%.

How many employees does AZN have?

Number of AZN employees currently stands at 94,300.

Link for AZN official website?

Official Website of AZN is: https://www.astrazeneca.com

How do I contact AZN?

AZN could be contacted at phone 442 037 495000 and can also be accessed through its website. AZN operates from 1 Francis Crick Avenue, Cambridge, CB2 0AA, United Kingdom.

How many shares of AZN are traded daily?

AZN stock volume for the day was 2.27M shares. The average number of AZN shares traded daily for last 3 months was 1.98M.

What is the market cap of AZN currently?

The market value of AZN currently stands at $302.65B with its latest stock price at $195.15 and 1.55B of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	94300
Beta	0.21
Sales or Revenue	$45.81B
5Y Sales Change%	0.681%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Drug Manufacturers - General

AZN Company Profile and Key Details

AstraZeneca

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Shareholding & Insider Activity

Dividend & Fair Value

Company Overview

Valuation Metrics

Key Takeaways

Price Forecast & Outlook